• 1
    Rothman S. Physiology of itching. Physiol Rev 1941: 11: 357381.
  • 2
    Hanifin J M, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980: 11 (Suppl. ): 4447.
  • 3
    Koblenzer C S. Itching and the atopic skin. J Allergy Clin Immunol 1999: 11: S109S113.
  • 4
    Andrew D, Craig A D. Spinothalamic lamina I neurons selectively sensitive to histamin: a central neuronal pathway for itch. Nat Neurosci 2001: 11: 7277.
  • 5
    Handwerker H O. Sixty years of C-fiber recordings from animal and human skin nerves: historical notes. Prog Brain Res 1996: 11: 3951.
  • 6
    Schmelz M, Schmidt R, Bickel A, Handwerker H O, Torebjork H E. Specific C-receptors for itch in human skin. J Neurosci 1997: 11: 80038008.
  • 7
    Schmelz M. A neuronal pathway for itch. Nat Neurosci 2001: 11: 810.
  • 8
    Tobin D, Nabarro G, De La Faille H B, Van Vloten W A, Van Der Putte S C J, Schuurman H J. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992: 11: 613622.
  • 9
    Sugiura H, Omoto M, Hirota Y, Danno K, Uehara M. Density and fine structure of peripheral nerves in various skin lesions at atopic dermatitis. Arch Derm Res 1997: 11: 125131.
  • 10
    Urashima R, Mihara M. Cutaneous nerves in atopic dermatitis. A histological, immunohistochemical and electron microscopic study. Virchows Arch 1998: 11: 363370.
  • 11
    Pincelli C, Fantini F, Massimi P, Girolomoni G, Seidenari S, Giannetti A. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol 1990: 11: 745750.
  • 12
    Osterle L S, Cowen T, Rustin M H. Neuropeptides in the skin of patients with atopic dermatitis. Clin Exp Dermatol 1995: 11: 462467.
  • 13
    Albers K M, Wright D E, Davis B M. Overexpression of nerve growth factor in epidermis of transgenic mice causes hypertrophy of peripheral nerve system. J Neurosci 1994: 11: 14221432.
  • 14
    Pincelli C, Sevignani C, Manfredini R. Expression and function of nerve growth factor and nerve growth factor receptor on cultured keratinocytes. J Invest Dermatol 1994: 11: 1318.
  • 15
    Mihm MC, Soter N A, Dvorak H F, Austen K F. The structure of normal skin and the morphology of atopic eczema. J Inv Dermatol 1976: 11: 305312.
  • 16
    Prose P H, Sedlis E. Morphologic and histochemical studies of atopic eczema in infants and children. J Invest Dermatol 1960: 11: 149165.
  • 17
    Kaji A, Shigematsu H, Fujita K, Maeda T, Watanabe S. Parasympathetic innervation of cutaneous blood vessels by vasoactive intestinal polypeptide-immunoreactive and acetylcholinesterase-positive nerves: histochemical and experimental study on rat lower lip. Neuroscience 1988: 11: 353.
  • 18
    Advenier C, Devillier P. Neurokinins and the skin. Allerg Immunol 1993: 11: 280282.
  • 19
    Brain S D, Williams T J. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 1985: 11: 855860.
  • 20
    Wallengren J, Badendick K, Sundler F, Hakanson R, Zander E. Innervation of the skin of the forearm in diabetic patients: relation to nerve function. Acta Derm Venereol 1995: 11: 3742.
  • 21
    Heyer G, Vogelsang M, Hornstein O P. Acetylcholine is an inducer of itching in patients with atopic dermatitis. J Dermatol 1997: 11: 621625.
  • 22
    Schallreuter K U. Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. J Invest Dermatol Symp Proc 1997: 11: 3740.
  • 23
    Röcken M, Schallreuter K, Renz H, Szentivanyi A. What exactly is ‘atopy’? Exp Dermatol 1998: 11: 97104.
  • 24
    Grando S A. Biological functions of keratinocyte cholinergic receptors. J Invest Dermatol Symp Proc 1997: 11: 4148.
  • 25
    Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000: 11: 457487.
  • 26
    Königstein H. Experimental study of itch stimuli in animals. Arch Derm Syph 1948: 11: 829849.
  • 27
    Darsow U, Derzezga A, Fritsch N et al. Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol 2000: 11: 10291033.
  • 28
    Heyer G, Hornstein O P, Handwerker H O. Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. J Invest Dermatol 1989: 11: 492496.
  • 29
    Scholzen T, Armstrong C A, Bunnett N W, Luger T A, Olerud J E, Ansel J C. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune system. Exp Dermatol 1998: 11: 8196.
  • 30
    Steinhoff M, Armstrong C, Scholzen T, et al. Neurocutaneous control of inflammation. In: Fitzpatrick, T B, Norris, D A, Kupper, T S, eds. Immune Mechanisms in Cutaneous Disease, 2nd edn. New York: Marcel Dekker Inc., in press.
  • 31
    Ansel J C, Kaynard Ah, Armstrong C A, Olerud J, Bunnett N, Payan D. Skin–nervous system interactions. J Invest Dermatol 1996: 11: 198204.
  • 32
    Rukwied R, Heyer G. Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylcholine in atopic eczema patients and healthy controls. Arch Dermatol Res 1998: 11: 198204.
  • 33
    Heyer G, Ulmer F J, Schmitz J, Handwerker H O. Histamine-induced itch and alloknesis (itchy skin) in atopic eczema patients and controls. Acta Derm Venereol 1995: 11: 348352.
  • 34
    Wahlgren C F. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy 1992: 11: 6575.
  • 35
    Wahlgren C F. Measurement of itch. Semin Dermatol 1995: 11: 277284.
  • 36
    Weidner C, Klede M, Rukwied R et al. Acute effects of Substance P and calcitonin gene-related peptide in human skin – a microdialysis study. J Invest Dermatol 2000: 11: 10151020.
  • 37
    Fjellner B, Hägermark Ö. Studies on pruritogenic and histamine-releasing effects of some putative peptide neurotransmitters. Acta Derm Venereol 1981: 11: 245250.
  • 38
    Fantini F, Pincelli C, Massimi P, Giannetti A. Neuropeptide-like immunoreactivity in skin lesions of atopic dermatitis and psoriasis. Br J Dermatol 1990: 11: 838839.
  • 39
    Pincelli C, Fantini F, Massimi P, Giannetti A. Neuropeptide Y-like immunoreactivity in Langerhans cells from patients with atopic dermatitis. Int J Neurosci 1990: 11: 219220.
  • 40
    Anand P, Springall D R, Blank M A, Sellu D, Polak J M, Bloom S R. Neuropeptides in skin disease: increased VIP in eczema and psoriasis but not axillary hyperhidrosis. Br J Dermatol 1991: 11: 547549.
  • 41
    Pincelli C, Fantini F, Romualdi P, Lesa G, Giannetti A. Skin levels of vasoactive intestinal polypeptide in atopic dermatitis. Arch Dermatol Res 1991: 11: 230232.
  • 42
    Fantini F, Pincelli C, Romualdi P, Donatini A, Giannetti A. Substance P levels are decreased in lesional skin of atopic dermatitis. Exp Dermatol 1992: 11: 127128.
  • 43
    Giannetti A, Fantini F, Cimitan A, Pincelli C. Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis. Acta Derm Venereol 1992: 11 (Suppl. ): 9092.
  • 44
    Bernstein J E, Parish L C, Rapaport M, Rosenbaum M M, Roenigk H H. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986: 11: 504507.
  • 45
    Ellis C N, Berberian B, Sulica V I, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993: 11: 438442.
  • 46
    Reimann S, Luger T, Metze D. Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz. Hautarzt 2000: 11: 164172.
  • 47
    Ständer S, Luger T, Metze D. Effective treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001: 11: 471478.
  • 48
    Caterina M J, Schumacher M A, Tominaga M, Rosen T A, Levine J D, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997: 11: 816824.
  • 49
    Dray A. Neuropharmacological mechanisms of capsaicin and related substances. Biochem Pharmacol 1992: 11: 611615.
  • 50
    Fjellner B, Hägermark Ö. Potentiation of histamine-induced itch and flare responses in human skin by the encephalin analogue FK 33-824, β-endorphin and morphine. Arch Derm Res 1982: 11: 2937.
  • 51
    Bernstein J E, Grinzi R A. Butorphanol-induced pruritus antagonized by naloxone. J Am Acad Dermatol 1981: 11: 227228.
  • 52
    Leung D V, Schneeberger E E, Gerha R S. The presence of IgE in macrophages and dendritic cells infiltrating into the skin lesions of atopic dermatitis. Clin Immunol Immunopathol 1987: 11: 328.
  • 53
    Fjellner B, Hägermark Ö. The influence of the opiate antagonist naloxone on experimental pruritus. Acta Derm Venereol 1984: 11: 7375.
  • 54
    Stein C. The control of pain in peripheral tissue by opiods. N Engl J Med 1995: 11: 16851690.
  • 55
    Bernstein J E, Swift R M. Relief of intractable pruritus with naloxone. Arch Dermatol 1979: 11: 13661367.
  • 56
    Summerfield J A. Pain, itch and endorphins. Br J Dermatol 1981: 11: 725726.
  • 57
    Hägermark Ö. Peripheral and central mediators of itch. Skin Pharmacol 1992: 11: 18.
  • 58
    Summerfield J A. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol 1980: 11: 180183.
  • 59
    Metze D, Reimann S, Beissert S, Luger T A. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999: 11: 533539.
  • 60
    Penning J P, Samson B, Baxter A D. Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine. Can J Anaesth 1988: 11: 559604.
  • 61
    Bergasa N V, Alling D W, Talbot T L et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995: 11: 161167.
  • 62
    Metze D, Reimann S, Luger T A. Effective treatment of pruritus with naltrexone, an orally active opiate antagonist. Ann N Y Acad Sci 1999: 11: 430432.
  • 63
    Heyer G R, Hornstein O P. Recent studies of cutaneous nociception in atopic and non-atopic subject. J Dermatol 1999: 11: 7786.
  • 64
    Heyer G R, Dotzer M, Diepgen T L, Handwerker H O. Opiate and H1 antagonists effects on histamine induced pruritus and alloknesis. Pain 1997: 11: 239243.
  • 65
    Georgala S, Schulpis K H, Papaconstantinou E D, Stratigos J. Raised β-endorphin serum levels in children with atopic dermatitis and pruritus. J Dermatol Sci 1994: 11: 125128.
  • 66
    Monroe E W. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 1989: 11: 135136.
  • 67
    Banerji D, Fox R, Seleznick M, Lockey R. Controlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis. J Allergy Clin Immunol 1988: 11: 252 (Abstract).
  • 68
    Burch J R, Harrison P V. Opiates, sleep and itch. Clin Exp Dermatol 1988: 11: 418419.
  • 69
    Grando S A, Kist D A, Qui M, Dahl M V. Human keratinocytes synthesize, secrete and degrade acetylcholine. J Invest Dermatol 1993: 11: 3236.
  • 70
    Grando S A, Zelickson B D, Kist D A. Keratinocyte muscarinic acetylcholine reports: Immunolocalisation and partial characterization. J Invest Dermatol 1995: 11: 95100.
  • 71
    Scott A. Acetylcholine in normal and disease skin. Br J Dermatol 1962: 11: 317322.
  • 72
    Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 2000: 11: 11141120.
  • 73
    Rukwied R, Heyer G. Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. Exp Dermatol 1999: 11: 3945.
  • 74
    Lewis T. The Blood Vessels of the Human Skin and Their Responses. London: Shaw and Sons, 1927.
  • 75
    Lewis T, Grant R T, Marvin H M. Vascular reactions of the skin to injury. Heart 1929: 11: 139160.
  • 76
    Williams D H. Skin temperature reaction to histamine in atopic dermatitis (disseminated neurodermatitis). J Invest Dermatol 1938: 11: 119129.
  • 77
    Johnson H H, DeOreo G A, Lascheid W P, Mitchell F. Skin histamine levels in chronic atopic dermatitis. J Invest Dermatol 1960: 11: 237238.
  • 78
    Juhlin L. Localization and content of histamine in normal and diseased skin. Acta Derm Venereol 1967: 11: 383391.
  • 79
    Ruzicka T, Glück S. Cutaneous histamine levels in histamine releasability from the skin in atopic dermatitis and hyper-IgE syndrome. Arch Derm Res 1983: 11: 4144.
  • 80
    Uehara M. Reduced histamine reaction in atopic dermatitis. Arch Dermatol 1982: 11: 244245.
  • 81
    Heyer G, Koppert W, Martus P, Handwerker H O. Histamine and cutaneous nociception: Histamine-induced responses in patients with atopic eczema, psoriasis and urticaria. Acta Derm Venereol 1998: 11: 123126.
  • 82
    Heyer G, Hornstein O P, Handwerker H O. Reactions to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients. Acta Derm Venerol 1991: 11: 291295.
  • 83
    Heyer G. Abnormal cutaneous neurosensitivity in atopic skin. Acta Derm Venereol 1992: 11 (Suppl. ): 9394.
  • 84
    Wahlgren C F, Hägermark Ö, Bergström R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990: 11: 545551.
  • 85
    Shelley W, Arthur R. The neurohistology and neurophysiology of the itch sensation in man. Arch Dermatol 1957: 11: 296323.
  • 86
    Hägermark Ö, Rajka G, Bergvist U. Experimental itch in human skin elicited by rat mast cell chymase. Acta Derm Venereol 1972: 11: 125128.
  • 87
    Bernstein J E. Capsaicin in dermatological disease. Semin Dermatol 1988: 11: 304309.
  • 88
    Jarvikallio A, Naukkarinen A, Harvima I T, Aalto M L, Horsmanheimo M. Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 1997: 11: 871877.
  • 89
    Steinhoff M, Vergnolle N, Young Sh et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000: 11: 151158.
  • 90
    Harvima I T, Naukkarinen A, Harvima R J, Horsmanheimo M. Enzyme- and immunohistochemical localization of mast cell tryptase in psoriatic skin. Arch Dermatol Res 1989: 11: 387391.
  • 91
    Naukkarinen A, Harvima I T, Aalto M L, Horsmanheimo M. Mast cell tryptase and chymase are potential regulators of neurogenic inflammation in psoriatic skin. Int J Dermatol 1994: 11: 361366.
  • 92
    Damsgaard T E, Olesen A B, Sorensen F B, Thestrup-Pedersen K, Schiotz P O. Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. Arch Dermatol Res 1997: 11: 256260.
  • 93
    Steinhoff M, Corvera C U, Thoma M S et al. Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 1999: 11: 282294.
  • 94
    Steinhoff M, Brzoska T, Shpacovitch V, Fastrich M, Luger T A. Proteinase-activated receptor-2 induces cytokine release and upregulation of cell adhesion molecules in human dermal microvascular endothelial cells. J Inv Dermatol 2002: 11in press.
  • 95
    Gaspari A A, Lotze M T, Rosenberg S A, Stern J B, Katz S I. Dermatologic changes associated with interleukin 2 administration. JAMA 1987: 11: 16241629.
  • 96
    Wahlgren C F, Scheynius A, Hägermark Ö. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990: 11: 323329.
  • 97
    Van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol 1987: 11: 166167.
  • 98
    Wahlgren C F, Tengvall Linder M, Hägermark Ö, Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995: 11: 572580.
  • 99
    Darsow U, Scharein R, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumor nekrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997: 11: 415417.
  • 100
    Martin H A. Bradykinin potentiates the chemoresponsiveness of rat cutaneous C-fibre polymodal nociceptors to interleukin-2. Arch Physiol Biochem 1996: 11: 229238.
  • 101
    Cremer B, Heimann A, Dippel E, Czarnetzki B M. Pruritogenic effects of mitogen stimulated peripheral blood mononuclear cells in atopic eczema. Acta Derm Venerol 1995: 11: 426428.
  • 102
    Grothe C, Heese K, Meisinger C et al. Expression of interleukin-6 and its receptor in the sciatic nerve and cultured Schwann cells: relation to 18-kD fibroblast growth factor-2. Brain Res 2000: 11: 172181.
  • 103
    Nordlind K, Chin L B, Ahmed A A, Brakenhoff J, Theodorsson E, Liden S. Immunohistochemical localization of interleukin-6-like immunoreactivity to peripheral nerve-like structures in normal and inflamed human skin. Arch Dermatol Res 1996: 11: 431435.
  • 104
    Lippert U, Hoer A, Möller A, Ramboer I, Cremer B, Henz B M. Role of antigen-induced cytokine released in atopic pruritus. Int Arch Allergy Immunol 1998: 11: 3639.
  • 105
    Kanai H, Nagashima A, Hirakata E et al. The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialysis patients. Life Sci 1995: 11: 207213.
  • 106
    Wahlgren C F, Hägermark Ö, Bergstrom R. Patients' perception of itch induced by histamine, compound 48/80 and wool fibres in atopic dermatitis. Acta Derm Venereol 1991: 11: 488494.
  • 107
    Sticherling M, Bornscheuer E, Schröder J M, Christophers E. Immunohistochemical studies on NAP-1/Il-8 in contact eczema and atopic dermatitis. Arch Dermatol Res 1992: 11: 8285.
  • 108
    Kimata H, Lindley I. Detection of plasma interleukin-8 in atopic dermatitis. Arch Dis Child 1994: 11: 119122.
  • 109
    Hatano Y, Katagiri K, Takayasu S. Increased levels in vivo of mRNAs for IL-8 and macrophage inflammatory protein-1 alpha (MIP-1 alpha), but not of RANTES mRNA in peripheral blood mononuclear cells of patients with atopic dermatitis (AD). Clin Exp Immunol 1999: 11: 237243.
  • 110
    Yousefi S, Hemmann S, Weber M et al. IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma. J Immunol 1995: 11: 54815490.
  • 111
    Reinhold U, Kukel S, Brzoska J, Kreysel H W. Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993: 11: 5863.
  • 112
    Stevens S R, Hanifin J M, Hamilton T, Tofte S J, Cooper K D. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998: 11: 799804.
  • 113
    Reinhold U, Wehrmann W, Kukel S, Kreysel H W. Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities. Clin Exp Immunol 1990: 11: 374379.
  • 114
    Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol 2000: 11: 11081112.
  • 115
    Velaquez J R, Lacy P, Moqbel R. Replenishment of RANTES mRNA expression in activated eosinophils from atopic asthmatics. Immunology 2000: 11: 591599.
  • 116
    Akdis C A, Akdis M, Trautmann A, Blaser K. Immune regulation in atopic dermatitis. Curr Opin Immunol 2000: 11: 641646.
  • 117
    Yamamoto J, Adachi Y, Onoue Y et al. CD 30 expression on circulation memory CD4+ T cells as a Th2-dominated situation in patients with atopic dermatitis. Allergy 2000: 11: 10111018.
  • 118
    Czarnetzki B M, Csato M. Comparative studies on human eosinophil migration towards platelet-activating factor and leukotriene B4. Int Arch Allergy Appl Immunol 1989: 11: 191193.
  • 119
    Sigal C E, Valone F H, Holtzmann M J, Goetzl E J. Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC). J Clin Immunol 1987: 11: 179184.
  • 120
    Weller P F, Lee C W, Foster D W, Corey E J, Austen K F, Lewis R A. Generation and metabolism of 5-lipoxygenase pathway leukotriens by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci USA 1983: 11: 76267630.
  • 121
    Lebel B, Venencie P Y, Saurat Jh, Soubrane C, Paupe J. Anti-IgE induced histamine release from basophils in children with atopic dermatitis. Acta Derm Venereol 1980: 11 (Suppl.): 5759.
  • 122
    Von Der Helm D, Ring J, Dorsch W. Comparison of histamine release and prostaglandin E2 production of human basophils in atopic and normal individuals. Arch Derm Res 1987: 11: 536542.
  • 123
    Bull H A, Courtney P F, Bunker C B, Rustin M H, Pearce F L, Dowd P M. Basophil mediator release in atopic dermatitis. J Invest Dermatol 1993: 11: 305309.
  • 124
    RajkaG, ed. Essential Aspects of Atopic Dermatitis. Berlin: Springer Verlag, 1989: 5769.
  • 125
    Hanifin J M. Pharmacophysiology of atopic dermatitis. Clin Rev Allergy 1986: 11: 4365.
  • 126
    Morren M A, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H. Atopic dermatitis: triggering factors. J Am Acad Dermatol 1994: 11: 467473.
  • 127
    Werner Y. The water content of the stratum corneum in patients with atopic dermatits. Measurement with the corneometer CM 420. Acta Derm Venereol 1986: 11: 281284.
  • 128
    Werner Y, Lindberg M, Forslind B. Membrane-coating granules in ‘dry’ non-eczematous skin of patients with atopic dermatitis. A quantitative electron microscopic study. Acta Derm Venereol 1987: 11: 385390.
  • 129
    Fartasch M, Diepgen T L. The barrier function in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids? Acta Derm Venereol 1992: 11 (Suppl.): 2631.
  • 130
    Hägermark Ö. The pathophysiology of itch. In: RuzickaT, ed. Handbook of Atopic Eczema. Berlin: Springer Verlag 1991: 278286.
  • 131
    Wahlgren C F. Itch and atopic dermatitis. J Dermatol 1999: 11: 770779.
  • 132
    Yoshiike T, Aikawa Y, Sindhvananda J et al. Skin barrier defect in atopic dermatitis: increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline. J Dermatol Sci 1993: 11: 9296.
  • 133
    Beltrani V S. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol 1999: 11: S87S98.
  • 134
    Hanifin J M. Basic and clinical aspects of atopic dermatitis. Ann Allergy 1984: 11: 386393.
  • 135
    Rovensky J, Saxl O. Differences in the dynamics of sweat secretion in atopic children. J Invest Dermatol 1964: 11: 171176.
  • 136
    Metze D, Luger T. Nervous system in the skin. In: New Basic Science in Dermatology: the Biology of the Skin,in press.
  • 137
    Fruhstorfer H, Hermanns M, Latzke L. The effects of thermal stimulation on clinical and experimental itch. Pain 1986: 11: 259269.
  • 138
    Graham D T, Wolf S. The relation of eczema to attitude and vascular reactions of the human skin. J Laboratory Clin Med 1953: 11: 238.
  • 139
    Bendsoe N, Bjornberg A, Asnes H. Itching from wool fibres in atopic dermatitis. Contact Dermatitis 1987: 11: 2122.
  • 140
    Ekblom A, Fjellner B, Hansson P. The influence of mechanical vibratory stimulation and transcutaneous electrical nerve stimulation on experimental pruritus induced by histamine. Acta Physiol Scand 1984: 11: 361367.
  • 141
    Fisher A A. Nonallergic ‘itch’ and ‘prickly’ sensation to wool fibers in atopic and nonatopic persons. Cutis 1996: 11: 323324.
  • 142
    Hogan D, Danaker C, Maibach H I. Contact dermatitis risk factors and rehabilitation. Semin Dermatol 1994: 11: 467473.
  • 143
    Sicherer S H, Sampson H A. Food hypersensitivity and atopic dermatitis. Pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999: 11: 114122.
  • 144
    Griesemer R D. Emotionally triggered disease in a dermatological practice. Psychiatr Ann 1978: 11: 4956.
  • 145
    Niemeier V, Kupfer J, Gieler U. Observations during an itch-inducing lecture. Dermatol Psychosom 2000: 11: 1518.
  • 146
    Fjellner B, Arnetz B B, Eneroth P, Kallner A. Pruritus during standardized mental stress. Relationship to psychoneuroendocrine and metabolic parameters. Acta Derm Venerol 1985: 11: 199205.
  • 147
    Fjellner B, Arnetz B B. Psychological predictors of pruritus during mental stress. Acta Derm Venereol 1985: 11: 504508.
  • 148
    Metze D, Reimann S, Luger T. Juckreiz-Symptom oder Krankheit. In: Plewig, G, Drzybilia, B, eds. Fortschritte der praktischen Dermatologie und Venerologie. Berlin: Springer Verlag, 1997: 7786.
  • 149
    Koblenzer C S. Psychologic and Psychiatric Aspects of Itching. In: Bernhard, JD, ed. Itch mechanisms and management of pruritus. New York: McGraw-Hill, 1994: 347365 .
  • 150
    Gupta M A, Gupta A K, Schork N J, Ellis C N. Depression modulates pruritus perception. A study of pruritus in psoriasis, atopic dermatitis and chronic idiopathic urticaria. Psychosom Med 1994: 11: 3640.
  • 151
    Cormia F E. Experimental histamine pruritus I. Influence of physical and psychological factors on threshold reactivity. J Invest Dermatol 1952: 11: 2134.
  • 152
    Arnetz B B, Fjellner B, Eneroth P, Kallner A. Endocrine and dermatological concomitants of mental stress. Acta Derm Venereol 1991: 11 (Suppl.): 912.
  • 153
    Buhk H, Muthny F A. Psychophysiologische und psychoneuroimmunologische Ergebnisse zur Neurodermitis. Hautarzt 1997: 11: 511.
  • 154
    Hermanns N, Scholz O B. Kognitive Einflüsse auf einen histamininduzierten Juckreiz und Quaddelbildung bei der atopischen Dermatitis. Verhaltensmod Verhaltensmed 1992: 11: 171194.
  • 155
    Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol 1995: 11: 624635.
  • 156
    Shenefelt P D. Hypnosis in dermatology. Arch Dermatol 2000: 11: 393399.
  • 157
    Garg A, Chren M M, Sands L P et al. Psychological stress pertubs epidermal permeability barrier homeostasis. Arch Dermatol 2001: 11: 5359.
  • 158
    Singh L K, Pang X, Alexacos N, Letourneau R, Theoharides T C. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav Immun 1999: 11: 225239.
  • 159
    Schwarzer A, Scholz O B. Auswirkungen unterschiedlicher Aktivierungsbedingungen auf Patienten mit atopischer Dermatits. Verhaltensmod Verhaltensmed 1990: 11: 4558.
  • 160
    Wahlgren C F. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol 1991: 11 (Suppl.): 153.
  • 161
    Hanifin J M, Ling M R, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part I, efficacy. J Am Acad Dermatol 2001: 11: S28S38.
  • 162
    Jekler J, Larkö O. Combined UVA–UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study. J Am Acad Dermatol 1990: 11: 4953.
  • 163
    Luger T, Van Leent E J M, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2000: 11: 788794.
  • 164
    Neuber K, Schwartz I, Itschert G, Dieck A T. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000: 11: 385391.
  • 165
    Hansen E R, Buus S, Deleuran M, Andersen K E. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2000: 11: 13241326.
  • 166
    Hanifin J M, Schneider L C, Leung D Y et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993: 11: 189197.
  • 167
    Hoare C, Li Wan Po A, Williams H. Systemic review of treatment for atopic eczema. Health Technol Assess 2000: 11: 1191.
  • 168
    Aliaga A, Rodriguez M, Armijo M et al. Double-blind study of prednicarbate versus flucortin butyl ester in atopic dermatitis. Int J Dermatol 1996: 11: 131132.
  • 169
    Maloney J M, Morman M R, Stewart D M, Tarp M D, Brown J J, Rajagopalan R. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol 1998: 11: 128144.
  • 170
    Yosipovitch G, Szolar C, Hui X Y, Maibach H. High-potency topical corticosteroid rapidly decreases histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol 1996: 11: 118120.
  • 171
    Sabroe R A, Kennedy C T, Archer C B. The effects of topical doxepin on responses to histamine, substance P, and prostaglandin E2 in human skin. Br J Dermatol 1997: 11: 386390.
  • 172
    Drake L A, Millikan L E and the Doxepin Study Group. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol 1995: 11: 14031408.
  • 173
    Groene D, Martus P, Heyer G. Doxepin affects acetylcholine induced cutaneous reactions in atopic eczema. Exp Dermatol 2001: 11: 110117.
  • 174
    Shelley W B, Shelley E D, Talanin N Y. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996: 11: 143144.
  • 175
    Tamaki K. Antipruritic effect of macrolide antibiotics. J Dermatol 2000: 11: 6667.
  • 176
    Kimata H. High dose gammaglobin treatment for atopic dermatitis. Arch Dis Child 1998: 11: 107113.
  • 177
    Gelfand E W, Landwehr L P, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996: 11 (Suppl.): 6166.
  • 178
    Mills L B, Mordan L J, Roth H L, Winger E E, Epstein W L. Treatment of severe atopic dermatitis by topical immune modulation using dinitrochlorobenzene. J Am Acad Dermatol 2000: 11: 687689.
  • 179
    Yoshizawa Y, Matusi H, Izaki S, Kitamura K, Maibach H I. Topical dinitrochlorobenzene therapy in the treatment of refractory atopic dermatitis: systemic immunotherapy. J Am Acad Dermatol 2000: 11: 258262.
  • 180
    Hanifin J M, Chan S C, Cheng J B et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996: 11: 5156.
  • 181
    Fjellner B, Hägermark Ö. Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. Acta Derm Venereol 1985: 11: 409412.
  • 182
    Abeck D, Andersson T, Grosshans E et al. Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. Acta Derm Venereol 1997: 11: 449451.
  • 183
    Andoh T, Kuraishi Y. Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur J Pharmacol 1998: 11: 9396.
  • 184
    Gazelius B, Panolpoulos P, Odlander B, Claesson H E. Inhibition of intradental nerve excitability by leukotriene B4 and C4. Acta Physiol Scand 1984: 11: 141143.
  • 185
    Miyoshi M, Sakurai T, Kodama S. Clinical evaluation of urinary leukotriene E4 levels in children with atopic dermatitis. Arerugi 1999: 11: 11481152.
  • 186
    Carruci J A, Washenik K, Weinstein A, Shupack J, Cohen D E. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998: 11: 785786.
  • 187
    Zabawski E J, Kahn M A, Gregg L J. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999: 11: 10.
  • 188
    Woodmanse D P, Simon R A. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999: 11: 548552.
  • 189
    Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis. Prostaglandin E2 and leucotriene B4 are present in biologically active concentrations. J Allergy Clin Immunol 1989: 11: 450455.
  • 190
    Watanabe T, Kuroda Y. The effect of a newly developed ointment containing eicosapentaenoic acid and docosahexaenoic acid in the treatment of atopic dermatitis. J Med Invest 1999: 11: 173177.
  • 191
    Lieschke G J, Maher D, Cebon J et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med 1989: 11: 357364.